Matinas BioPharma Holdings said it received an August 31, 2026, notice from NYSE American that it does not meet continued listing standards requiring at least $2.0 million in stockholders’ equity under Section 1003(a)(i) of the NYSE American Company Guide. The company had $1.8 million in stockholders’ equity as of June 30, 2026, and reported losses from continuing operations and/or net losses in each of its five most recent fiscal years ended December 31, 2025. Matinas is also out of compliance with Sections 1003(a)(ii) and 1003(a)(iii). NYSE American accepted the company’s compliance plan on May 4, 2026, giving it until October 2, 2027, to regain compliance. The notice does not immediately affect the listing or trading of its common stock, although the company will remain designated as a noncompliant issuer with the .BC indicator. Matinas said its lipid nanocrystal (LNC) platform is being used to develop MAT2203, an oral potential treatment for invasive fungal infections, and that the therapy completed the Phase 2 EnACT study in HIV patients with cryptococcal meningitis.